NXL
Nexalin Technology, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$4.75
−6.85%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
+1238.3%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Dec 23, 2025 | White Mark · director, officer: CEO | A-Award | 1,000,000 | $0.83 |
| Dec 23, 2025 | Van Fleet Justin · officer: CFO | A-Award | 100,000 | $0.83 |
| Dec 23, 2025 | Owens David · director, officer: Chief Medical Officer | A-Award | 1,000,000 | $0.83 |
| Dec 23, 2025 | Shelton Carolyn Hamby · officer: Sr. VP - Quality - Regulatory | A-Award | 100,000 | $0.83 |
| Dec 23, 2025 | Hu Ben · director | A-Award | 100,000 | $0.83 |
| Dec 23, 2025 | Kazden Alan · director | A-Award | 100,000 | $0.83 |
| Sep 30, 2025 | OSSER LEONARD · 10 percent owner | A-Award | 83,333 | $0.00 |
| Sep 30, 2025 | Owens David · director, officer: Chief Medical Officer | A-Award | 36,459 | $0.00 |
| Sep 30, 2025 | Hu Ben · director | A-Award | 36,459 | $0.00 |
| Sep 30, 2025 | Kazden Alan · director | A-Award | 36,459 | $0.00 |
| Sep 12, 2025 | Shelton Carolyn Hamby · officer: Sr. VP - Quality - Regulatory | A-Award | 20,000 | $2.95 |
| Sep 12, 2025 | Owens David · director, officer: Chief Medical Officer | A-Award | 100,000 | $0.96 |
| Sep 12, 2025 | Owens David · director, officer: Chief Medical Officer | A-Award | 203,125 | $0.96 |
| Sep 12, 2025 | Elson Marilyn · 10 percent owner | Sale | 23,150 | $4.15 |
| Jul 21, 2025 | Elson Marilyn · 10 percent owner | A-Award | 30,000 | $1.15 |
| Jul 21, 2025 | Elson Marilyn · 10 percent owner | A-Award | 150,000 | $1.15 |
| Mar 13, 2025 | Shelton Carolyn Hamby · officer: Sr. VP - Quality, Regulatory | Purchase | 6,000 | $2.20 |
| Feb 27, 2025 | White Mark · director, officer: President and CEO | A-Award | 939,597 | $0.89 |
| Feb 27, 2025 | White Mark · director, officer: President and CEO | A-Award | 447,427 | $0.89 |
| Feb 27, 2025 | Owens David · director, officer: Chief Medical Officer | A-Award | 125,000 | $2.95 |
| Feb 27, 2025 | Owens David · director, officer: Chief Medical Officer | A-Award | 654,363 | $0.89 |
| Feb 27, 2025 | Owens David · director, officer: Chief Medical Officer | A-Award | 139,821 | $0.89 |
| Feb 10, 2025 | Shelton Carolyn Hamby · officer: Senior VP | A-Award | 90,620 | $0.66 |
| Feb 5, 2025 | Owens David · director, officer: Chief Medical Officer | Purchase | 1,000 | $3.10 |
| Feb 4, 2025 | Owens David · director, officer: Chief Medical Officer | Purchase | 1,000 | $2.98 |
| Jan 29, 2025 | Owens David · director, officer: Chief Medical Officer | A-Award | 262,500 | $0.94 |
| Jan 29, 2025 | Kazden Alan · director | Purchase | 262,500 | $0.94 |
| Jan 29, 2025 | Owens David · director, officer: Chief Medical Officer | Purchase | 1,500 | $2.70 |
| Jan 24, 2025 | Owens David · director, officer: Chief Medical Officer | Purchase | 1,000 | $2.70 |
| Jan 24, 2025 | Owens David · director, officer: Chief Medical Officer | Purchase | 2,000 | $2.50 |
Institutional positioning
13F filings over the trailing two quarters
New 13Increased 5Reduced 13Sold out 7
| Filer | Action | Shares | Filed |
|---|---|---|---|
| PEAK6 LLC | Reduced | 384,460 | May 14, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 247,037 | May 15, 2026 |
| PEAK6 LLC | Reduced | 240,210 | Aug 13, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Reduced | 139,583 | Aug 12, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 126,536 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Unchanged | 126,536 | Aug 13, 2026 |
| CITADEL ADVISORS LLC | New Position | 75,398 | Sep 2, 2026 |
| JANE STREET GROUP, LLC | Increased | 65,497 | Aug 14, 2026 |
| VANGUARD FIDUCIARY TRUST CO | New Position | 51,386 | May 8, 2026 |
| VANGUARD FIDUCIARY TRUST CO | Unchanged | 51,386 | Aug 13, 2026 |
| STATE STREET CORP | Unchanged | 32,300 | Aug 7, 2026 |
| STATE STREET CORP | Unchanged | 32,300 | May 15, 2026 |
| UBS Group AG | Increased | 26,825 | Aug 13, 2026 |
| NORTHERN TRUST CORP | Unchanged | 24,100 | May 14, 2026 |
| NORTHERN TRUST CORP | Unchanged | 24,100 | Aug 13, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Dec 23, 2025